Migraine
Not recruitingStudy on Atogepant for Preventing Menstrual Migraine in Women
Study on Atogepant for Preventing Menstrual Migraine in Women
Czechia- Participants:18–64 years
- Substances:Atogepant
- Sponsor:AbbVie Deutschland GmbH & Co. KG
Rare diseases
Investigational molecules
Locations
459 conditions with trials, the busiest first
1 397 trials across Europe, recruiting first
Study on Atogepant for Preventing Menstrual Migraine in Women
CzechiaStudy of AGuIX Nanoparticles and Temozolomide with Radiotherapy for Patients with Newly Diagnosed Glioblastoma
FranceStudy on the Effects of Doxorubicin and Temozolomide After Radiotherapy in Children and Young Adults with Glioblastoma
ItalyStudy on the Effectiveness and Safety of Levetiracetam XR for Patients with Drug-Resistant Partial Onset Epilepsy
BulgariaStudy of Amlenetug for Patients with Multiple System Atrophy
FranceStudy on the Effectiveness and Safety of Venglustat for Adults and Children with Gaucher Disease TYPE 3
FranceStudy on Pramipexole for Treating Restless Legs in Women with X-linked Adrenoleukodystrophy
The NetherlandsStudy Comparing Serratus Plane Block, Capsaicin, and Botulinum Toxin Type A for Chronic Pain in Post-Mastectomy Patients
FranceStudy on the Safety and Effectiveness of Methotrexate and Drug Combination for Children and Young Adults with High-Risk Metastatic Medulloblastoma
ItalyStudy on PRAX-628 for Adults with Focal Onset or Generalized Tonic-Clonic Seizures
GermanyStudy on the Effect of Cannabidiol (CBD) on Sleep Quality in Multiple Sclerosis Patients with Insomnia
The NetherlandsStudy on the Effects of Cladribine on Brain Cells in Patients with Multiple Sclerosis
FinlandThe therapies tested most often in Nervous system disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.